INVESTOR ACTION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Travere Therapeutics, Inc. and Encourages Investors with Losses to Contact the FirmAccesswire • 05/11/23
Travere Therapeutics (TVTX) Reports Q1 Loss, Tops Revenue EstimatesZacks Investment Research • 05/04/23
Travere Therapeutics stock slides 35% after announcing disappointing results from 2-year trial of kidney drugMarket Watch • 05/02/23
INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against Travere Therapeutics, Inc. and Encourages Investors with Losses to Contact the FirmBusiness Wire • 05/02/23
Travere Crashes 29% On A Disappointing Update From A Two-Year Kidney Disease TestInvestors Business Daily • 05/02/23
Travere Therapeutics Announces Topline Results from Two-Year Primary Efficacy Endpoint in Pivotal Phase 3 DUPLEX Study of Sparsentan in Focal Segmental GlomerulosclerosisGlobeNewsWire • 05/01/23
Travere Therapeutics (TVTX) Expected to Beat Earnings Estimates: Can the Stock Move Higher?Zacks Investment Research • 04/27/23
Travere Therapeutics Announces Interim Analysis from the Phase 3 PROTECT Study of FILSPARI™ (Sparsentan) in IgA Nephropathy Published in The Lancet and Presented at World Congress of Nephrology 2023GlobeNewsWire • 04/01/23
Travere Therapeutics Announces Late-Breaker Presentations of the Interim Analysis from the Phase 3 PROTECT Study of FILSPARI™ (Sparsentan) in IgA Nephropathy at the ISN World Congress of Nephrology and NKF Spring Clinical Meetings 2023GlobeNewsWire • 03/23/23
Travere Therapeutics to Present Abstracts at the Society for Inherited Metabolic Disorders 44th Annual Meeting and the American College of Medical Genetics and Genomics Annual Clinical Genetics Meeting 2023GlobeNewsWire • 03/14/23
Travere Therapeutics Announces Completion of Public Offering of Common Stock and Pre-Funded Warrants and Exercise in Full of Underwriters' Option to Purchase Additional SharesGlobeNewsWire • 03/03/23
Travere Therapeutics Announces Pricing of Public Offering of Common Stock and Pre-Funded WarrantsGlobeNewsWire • 03/01/23
Travere Therapeutics (TVTX) Reports Q4 Loss, Tops Revenue EstimatesZacks Investment Research • 02/23/23
Travere Therapeutics Reports Fourth Quarter and Full Year 2022 Financial ResultsGlobeNewsWire • 02/23/23
Travere Therapeutics Announces FDA Accelerated Approval of FILSPARITM (sparsentan), the First and Only Non-immunosuppressive Therapy for the Reduction of Proteinuria in IgA NephropathyGlobeNewsWire • 02/17/23